WHITE PLAINS, N.Y., Oct. 2, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced the appointment of Lee Greenberger, Ph.D., an executive with a significant oncology research and development background, as its new chief scientific officer.
In this role, Dr. Greenberger will be responsible for planning and executing the strategy for all LLS research programs, including grant funding programs, the Therapy Acceleration Program (TAP), as well as other research initiatives. He will guide LLS's efforts to translate innovative research into clinical trials that ultimately will pave the way for new therapies to treat blood cancers.
"LLS will benefit greatly from Lee's depth and breadth of experience in oncology, which will enable us to significantly enhance our ability to meet our ambitious strategic goals and deliver on LLS's mission to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families," said LLS Chief Mission Officer Louis DeGennaro, Ph.D.
Most recently, Greenberger was global head of search and diligence for oncology and immunology at Bristol-Myers Squibb where he examined opportunities for over 200 oncology companies and helped set the business strategy for oncology and immunology.
Prior to that, he served for six years as vice president for research at Enzon Pharmaceuticals where he was responsible for pre-clinical pharmacology, toxicology, process development, and analytical chemistry efforts associated with the discovery and development of oncology assets. Prior to Enzon, Lee held positions of increasing responsibility in the research organizations of Johnson & Johnson and Wyeth Pharmaceuticals, where he began his industry career in 1990 at American Cyanamid/Lederle Laboratories, which was later acquired by Wyeth. He was given the President's Award for his work at Wyeth.
Greenberger holds a bachelor's degree from the University of Rochester and a Ph.D. from Emory University. He has done post-doctoral work at Columbia University and was on faculty at the Albert Einstein College of Medicine. Greenberger has published more than 85 publications, mostly focused on oncology, during his research career.
About The Leukemia & Lymphoma Society Canada
The Leukemia & Lymphoma Society ® (LLS)is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS exists to find cures and ensure access to treatments for blood cancer patients.
Founded in 1949 andheadquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visitwww.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.